Convergence Investment Partners LLC bought a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,050 shares of the biopharmaceutical company’s stock, valued at approximately $1,016,000.
Other hedge funds have also bought and sold shares of the company. Patriot Financial Group Insurance Agency LLC grew its position in Alexion Pharmaceuticals by 62.8% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 280 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 108 shares in the last quarter. Simon Quick Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the 1st quarter worth $39,000. North Star Investment Management Corp. bought a new stake in shares of Alexion Pharmaceuticals during the 1st quarter worth $41,000. Credit Agricole S A boosted its holdings in shares of Alexion Pharmaceuticals by 25.0% during the 1st quarter. Credit Agricole S A now owns 500 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 100 shares during the period. Finally, Whittier Trust Co. boosted its holdings in shares of Alexion Pharmaceuticals by 90.0% during the 2nd quarter. Whittier Trust Co. now owns 475 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 225 shares during the period. 89.07% of the stock is owned by institutional investors.
Several analysts recently issued reports on ALXN shares. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and set a $107.00 price objective for the company. in a report on Monday, May 18th. Credit Suisse Group upped their price objective on shares of Alexion Pharmaceuticals from $142.00 to $147.00 and gave the stock an “outperform” rating in a report on Monday, June 1st. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 28th. Morgan Stanley upped their price objective on shares of Alexion Pharmaceuticals from $116.00 to $120.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Nomura reaffirmed a “buy” rating and set a $133.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 6th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $143.17.
Shares of ALXN stock traded down $2.32 during mid-day trading on Friday, reaching $102.49. The company’s stock had a trading volume of 2,158,967 shares, compared to its average volume of 1,587,144. Alexion Pharmaceuticals, Inc. has a 1-year low of $72.67 and a 1-year high of $125.52. The company has a market cap of $22.63 billion, a P/E ratio of 27.40, a PEG ratio of 0.81 and a beta of 1.46. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.82 and a current ratio of 4.79. The firm’s 50-day moving average is $110.49 and its two-hundred day moving average is $102.94.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $3.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.79. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%. The company had revenue of $1.44 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.95 EPS for the current year.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: What is the Euro STOXX 50 Index?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.